Metware
Latest round
- Series B
Last raised
- Apr 2024
Total raised
- $15M
Investors
- 4
About Metware
Established in 2015 and based in Wuhan, China, Metware is a biotech company that focuses on the development of innovative metabolomic technology. It has sub-branch offices in Shenzhen, Beijing, Changsha, and America. The company obtained over 50 patents, including 6 invention patents and 16 utility model patents. It has more than 400 employees, nearly 40% of whom are scientific researchers. The company engages in the development of innovative metabolomic technology. Metware's main business includes innovative metabolomic technology service CRO (Contract Research Organization), chronic metabolic disease prognosis kit development, and early tumour screening "liquid biopsy" metabolic kit development. The products can be used in cancer, metabolic disorders, infectious diseases, agriculture and breeding, microbiome, and other fields. The company's products can be used in application scenarios such as scientific research institutes, hospitals, and industrial enterprises.
Who invested in Metware
4 investors across 3 rounds
See all investors in Metware
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Metware
Who invested in Metware?
Metware has 4 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Metware raised?
Metware has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Metware last raise money?
Metware's most recent round on record is a Series B, in Apr 2024.
What does Metware do?
Established in 2015 and based in Wuhan, China, Metware is a biotech company that focuses on the development of innovative metabolomic technology.
Where is Metware headquartered?
Metware is headquartered in Wuhan, China.
Which VCs invest in companies like Metware?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Metware's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Metware? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.